Purpose: The hand is the most commonly affected site in osteoarthritis (OA). First carpometacarpal (CMC) and proximal interphalangeal (PIP) joint involvement often leads to pain, progressive loss of hand function and deformity. Synovitis is a common finding and is likely to be one cause of pain in this group. A specialist hand OA clinic was set up in 2006 with the aim of delivering high quality care based on the EULAR guidelines. The role of intra-articular steroid in these patients remains controversial, and we therefore examined the outcomes of 2 groups of patients from the clinic who received either first CMC or PIP joint injections as part of their treatment. We hypothesised that CMC joint injection would be more effective than PIP joint injection, and that presence of inflammation (high pain scores, raised CRP or presence of synovial power doppler signal on ultrasound) would predict clinical response. Methods: Sequential patients fulfilling ACR criteria for OA seen between October 2006 and October 2009 who received corticosteroid joint injection were followed prospectively. Clinical and hand therapy assessment, and ultrasound assessment for those with PIP joint disease was carried out at baseline. All patients were given education and an individualised treatment programme including joint protection and exercises, appropriate splinting and analgesics review. Worst pain score in the preceding week for the intervention joint (0-10) was recorded immediately prior to the injection and at later review. Range of joint motion, joint circumference and Jamar grip strength were recorded prior to injection, and at review. Patient subjective pain response to injection at 4 weeks (none, partial, good) was also recorded retrospectively. Results: 65 new patients were seen in the clinic during this time. Of these, 15 patients received at least one CMC joint injection and 15 patients received at least one PIP joint injection. 24 of these 30 patients were female. The mean ages of the CMC and PIP group were 62 and 70 years respectively. In the CMC joint group, 22 different joints were injected. The mean time to assessment following injection was 91 days (range 35-154). After 13 procedures, a good response was reported to injection (59%). In a further 7, there was a partial response (32%). 3 patients required subsequent re-injection of at least one CMC joint, and 2 patients proceeded to surgery during subsequent follow-up. 1 patient was lost to follow-up. In the PIP joint group, 23 different joints were injected. The mean time to assessment following injection was 130 days (range 49-210). A good response to injection was reported after 14 procedures (61%) with a further 6 resulting in a partial response (26%). On average, 1 point reduction on the pain scale, 7 degrees of increased range of motion, a 1 mm decrease in joint circumference, and 1.3 kg improvement in grip strength were measured at review, although data was not available for all patients. A high baseline pain score, raised CRP or power doppler signal evident on ultrasound were not seen more frequently in those with a good response to injection in either group (Table 1) .
Conclusions: Short-term good or partial responses to either CMC or PIP joint injection are more common in our experience than in other reports (91% and 87% respectively). It appears that some improvement in objective parameters in the PIP joint group is present at a mean interval of 4 months.
Our data support previous observations that many patients have synovial inflammation evident on ultrasound. However, the presence of high pain scores or biochemical or ultrasonographic inflammation did not appear to predict response to corticosteroid injection, although a controlled study would be required to accurately assess this. This was an observational study and the effects of injection cannot be separated from the effects of other interventions such as education, exercise and splinting. However, our data support the use of joint injection as part of a multi-disciplinary treatment programme for those with symptomatic hand osteoarthritis. Purpose: Hyaluronic acid (HA) injections are safe but costly interventions that are widely used for knee osteoarthritis (OA) despite views that evidence for their efficacy is weak. Indeed, systematic reviews have generated conflicting results, hampered by low quality of trials available for metaanalysis and possible conflicts of interest. However, these meta-analyses did not evaluate the post-injection trajectory of its therapeutic effect, an aspect that would provide meaningful insight into its effectiveness, nor did they benefit from the extent of data now available. Therefore, we performed a meta-analysis using fully current data to evaluate the magnitude of effect of hyaluronic acid at specified intervals post-treatment with adjustment for trial quality indicators. Methods: We searched Medline, EMBASE, CINAHL, BIOSIS, Cochrane database, Web of Science and Google Scholar from inception to March 2010 for human randomized clinical trials comparing hyaluronic acid vs. placebo for knee OA. We hand searched review articles, manuscripts and medical journal supplements, and contacted authors for unpublished data. Two reviewers independently assessed the quality of each trial and extracted means and variances for pain, function and stiffness. We computed effect sizes for mean change from baseline to weeks 4, 8, 12, 16, 20 and 24 using Hedges' g statistic. Effect sizes were pooled using random effects model. We defined "high quality trials" as those with N>100 also reporting intent-to-treat analysis, blinding, and allocation concealment. We performed sensitivity analyses by pooling high quality trials and multivariate analyses adjusting for correlation between time points. Results: The 54 eligible trials published during 1983 -2009 included 7545 participants with age range 45-72 yrs. The proportion of women ranged 28% -100%. There were 16 high quality trials (n = 3176) and 8 were unpublished (n = 963). Industry affiliation was present in 36 trials and unclear in 17; 1 trial was independent. The effect size for pain favored hyaluronic acid by week 4 (0.31; 95% CI 0.17, 0.45), reaching a peak at week 8 (0.46; 0.28, 0.65), and then trending downwards, with a residual detectable effect at week 24 (0.21; 0.10, 0.31) (Table 1 ). This therapeutic trajectory was consistent among the subset of high quality trials and on multivariate analysis adjusting for correlation between time points. The effect on function and stiffness also showed similar trajectory. 
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Conclusions:
This meta-analysis highlights the therapeutic trajectory of intra-articular hyaluronic acid for knee OA pain over six months following the intervention. With this additional perspective, we are able to infer that intra-articular hyaluronic acid is efficacious by 4 weeks, reaches its peak effectiveness at 8 weeks and exerts a residual detectable at 24 weeks (Figure 1) . On the other hand, the peak effect size (0.46; 0.28, 0.65), is greater than the published effects from other OA analgesics. The magnitude of effect is modest, and exceeds a minimally clinically significant threshold. Thus, its properties could have utility for certain clinical situations,
